Portside Wealth Group LLC Sells 28,616 Shares of Haleon plc (NYSE:HLN)

Portside Wealth Group LLC lowered its stake in Haleon plc (NYSE:HLN) by 61.2% in the 1st quarter, Holdings Channel reports. The firm owned 18,126 shares of the company’s stock after selling 28,616 shares during the quarter. Portside Wealth Group LLC’s holdings in Haleon were worth $173,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in HLN. Wellington Management Group LLP boosted its stake in Haleon by 67.5% in the 4th quarter. Wellington Management Group LLP now owns 15,328,325 shares of the company’s stock worth $146,232,000 after purchasing an additional 6,175,835 shares during the period. Point72 Asset Management L.P. bought a new stake in shares of Haleon during the 4th quarter valued at about $45,110,000. Raymond James Financial Inc. bought a new stake in shares of Haleon during the 4th quarter valued at about $42,193,000. FMR LLC boosted its position in shares of Haleon by 3.7% during the 4th quarter. FMR LLC now owns 108,827,814 shares of the company’s stock valued at $1,038,217,000 after acquiring an additional 3,909,545 shares during the last quarter. Finally, Bank Julius Baer & Co. Ltd Zurich bought a new stake in shares of Haleon during the 4th quarter valued at about $39,628,000. Institutional investors own 6.67% of the company’s stock.

Wall Street Analysts Forecast Growth

HLN has been the subject of a number of research analyst reports. HSBC reiterated a “hold” rating on shares of Haleon in a research report on Wednesday, March 5th. Morgan Stanley upgraded Haleon from an “equal weight” rating to an “overweight” rating and set a $11.25 price target for the company in a research report on Friday, May 9th. Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a research report on Friday. Hsbc Global Res downgraded Haleon from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, March 5th. Finally, Barclays reiterated an “overweight” rating on shares of Haleon in a research report on Tuesday, May 6th. Five equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $12.33.

Haleon Stock Performance

Shares of NYSE HLN opened at $11.07 on Friday. The stock has a market cap of $49.84 billion, a price-to-earnings ratio of 32.56, a P/E/G ratio of 2.82 and a beta of 0.31. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 1-year low of $8.25 and a 1-year high of $11.42. The stock’s 50-day moving average is $10.50 and its 200 day moving average is $10.03.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.